{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=assessment+only+control&page=70",
    "query": {
      "intervention": "assessment only control",
      "page": 70
    },
    "page_size": 10
  },
  "pagination": {
    "page": 70,
    "page_size": 10,
    "total_count": 4563,
    "total_pages": 457,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=assessment+only+control&page=71&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=assessment+only+control&page=69&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T09:34:02.781Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01107886",
      "title": "Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 18206,
      "start_date": "2010-05",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2014-07-17",
      "last_synced_at": "2026-11-19T09:34:02.781Z",
      "location_count": 202,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 199 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01107886"
    },
    {
      "nct_id": "NCT03800173",
      "title": "A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Marburg Virus Disease"
      ],
      "interventions": [
        {
          "name": "galidesivir",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioCryst Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2018-12-10",
      "completion_date": "2019-04-30",
      "has_results": true,
      "last_update_posted_date": "2021-07-23",
      "last_synced_at": "2026-11-19T09:34:02.781Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03800173"
    },
    {
      "nct_id": "NCT07055217",
      "title": "Effect of Mindfulness-based Neurofeedback for Adolescents With Elevated Repetitive Negative Thinking",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Repetitive Negative Thinking",
        "Neurofeedback"
      ],
      "interventions": [
        {
          "name": "Mindfulness Training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Mindfulness-based Neurofeedback (Real mbNF)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Sham mindfulness-based neurofeedback (Sham mbNF)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "13 Years to 21 Years"
      },
      "enrollment_count": 100,
      "start_date": "2025-11-04",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-11-19T09:34:02.781Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07055217"
    },
    {
      "nct_id": "NCT06063174",
      "title": "Stress & Resilience Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stress",
        "Stress, Psychological",
        "Stress, Physiological",
        "Stress, Emotional",
        "Stress Reaction"
      ],
      "interventions": [
        {
          "name": "Education Program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Think Well Program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Be Well Program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Eat Well Program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Sleep Well Program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Move Well Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 712,
      "start_date": "2023-06-30",
      "completion_date": "2024-10-30",
      "has_results": false,
      "last_update_posted_date": "2025-04-15",
      "last_synced_at": "2026-11-19T09:34:02.781Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06063174"
    },
    {
      "nct_id": "NCT00862459",
      "title": "Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Diseases",
        "Spinal Cord Diseases"
      ],
      "interventions": [
        {
          "name": "Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)",
          "type": "DRUG"
        },
        {
          "name": "Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)",
          "type": "DRUG"
        },
        {
          "name": "Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)",
          "type": "DRUG"
        },
        {
          "name": "OptiMARK~0.1 mmol/kg BW",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 237,
      "start_date": "2005-08",
      "completion_date": "2007-03",
      "has_results": true,
      "last_update_posted_date": "2014-01-13",
      "last_synced_at": "2026-11-19T09:34:02.781Z",
      "location_count": 20,
      "location_summary": "Sacramento, California • San Diego, California • Jacksonville, Florida + 16 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00862459"
    },
    {
      "nct_id": "NCT05717686",
      "title": "A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "AHB-137 injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AusperBio Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 64,
      "start_date": "2023-02-28",
      "completion_date": "2025-01-07",
      "has_results": false,
      "last_update_posted_date": "2025-02-14",
      "last_synced_at": "2026-11-19T09:34:02.781Z",
      "location_count": 4,
      "location_summary": "Redwood City, California • Baltimore, Maryland • New York, New York + 1 more",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05717686"
    },
    {
      "nct_id": "NCT03682770",
      "title": "Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peanut Allergy"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching dupilumab",
          "type": "DRUG"
        },
        {
          "name": "AR101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 148,
      "start_date": "2018-10-03",
      "completion_date": "2021-07-23",
      "has_results": true,
      "last_update_posted_date": "2024-02-07",
      "last_synced_at": "2026-11-19T09:34:02.781Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03682770"
    },
    {
      "nct_id": "NCT05412641",
      "title": "Evaluation of the FELLAS Responsible Fatherhood Project",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Responsible Fatherhood"
      ],
      "interventions": [
        {
          "name": "Intervention - Responsible Fatherhood Programming",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Partnership for Maternal & Child Health of Northern New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 540,
      "start_date": "2021-06-20",
      "completion_date": "2025-05-01",
      "has_results": false,
      "last_update_posted_date": "2022-06-09",
      "last_synced_at": "2026-11-19T09:34:02.781Z",
      "location_count": 1,
      "location_summary": "Newark, New Jersey",
      "locations": [
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05412641"
    },
    {
      "nct_id": "NCT06944925",
      "title": "A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "BBT002",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bambusa Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 286,
      "start_date": "2025-05-08",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-11-19T09:34:02.781Z",
      "location_count": 3,
      "location_summary": "Bowling Green, Kentucky • Owensboro, Kentucky • New York, New York",
      "locations": [
        {
          "city": "Bowling Green",
          "state": "Kentucky"
        },
        {
          "city": "Owensboro",
          "state": "Kentucky"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06944925"
    },
    {
      "nct_id": "NCT02093559",
      "title": "Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among Naloxone Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Opioid-Related Disorders",
        "Drug Overdose"
      ],
      "interventions": [
        {
          "name": "Brief counseling Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "San Francisco Department of Public Health",
      "sponsor_class": "OTHER_GOV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 63,
      "start_date": "2014-07",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2023-11-22",
      "last_synced_at": "2026-11-19T09:34:02.781Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02093559"
    }
  ]
}